Vutrisiran can improve and maintain functional capacity and quality of life in patients with transthyretin amyloidosis with ...

but serial echocardiograms did not show restrictive cardiomyopathy or progression of the ventricular wall or septal thickness, ruling out cardiac amyloid involvement. Bone marrow biopsy and fat ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis cardiomyopathy, as Alnylam Pharmaceuticals announced expanded FDA approval.

“Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive disease [that] sadly impairs the quality of life, functional capacity and health status of patients, as described by ...

The FDA has approved BridgeBio Pharma's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market showdown with its larger rival Pfizer.

The Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light to acoramidis (Beyonttra) for adult ...

The EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion, recommending a change to the terms of the marketing ...

Tafamidis and tafamidis meglumine may help treat transthyretin amyloid cardiomyopathy (ATTR-CM). Medicare Part D prescription drug plans may cover the cost of these medications. Transthyretin ...

This would be with respect to the advancement of nexiguran ziclumeran [nex-z] as a treatment option for patients with ATTR Amyloidosis with cardiomyopathy [ATTR-CM]. The use of this drug ...

While Alnylam has not released an official statement regarding the financial impact of the CHMP’s recommendation, investors have responded favorably to the news. The stock’s upward movement reflects ...